Eligible ages
Adults 65+
Compensation
Up to $2,200 for time and effort
Who is eligible
- Have a BMI of at least 35 kg/m2 and be at least 65 years of age - Do not have Type 1 or Type 2 Diabetes - Additional criteria may apply and will be reviewed with you
What's involved
This research study is evaluating whether an investigational daily oral medication called enobosarm, taken alongside weekly semaglutide (Wegovy) injections, can support healthier body composition during weight loss—all participants receive Wegovy and are randomly assigned to also take either enobosarm or a placebo capsule. Participation involves about 68 weeks of treatment with clinic visits roughly every four weeks, including body weight checks, body-composition scans, physical function tests, and standard safety assessments.
Where this study is run
ALSA Research – Manhattan
425 5th Avenue, 6th Floor, Unit 602, New York, NY 10016